Exelixis to Release Fourth Quarter and Full Year 2019 Financial Results on Tuesday, February 25, 2020
February 12 2020 - 4:05PM
Business Wire
–Conference Call and Webcast to Follow at 5:00
p.m. EST / 2:00 p.m. PST–
Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth
quarter and full year 2019 financial results will be released on
Tuesday, February 25, 2020 after the markets close. At 5:00 p.m.
EST / 2:00 p.m. PST, Exelixis management will host a conference
call and webcast to discuss the results and provide a general
business update. Access to the event is available via the Internet
from the company’s website.
To access the webcast link, log onto www.exelixis.com and
proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s
website at least 15 minutes prior to the conference call to ensure
adequate time for any software download that may be required to
listen to the webcast. Alternatively, please call 855-793-2457
(domestic) or 631-485-4921 (international) and provide the
conference call passcode 9168158 to join by phone.
A telephone replay will be available until 8:00 p.m. EST on
February 27, 2020. Access numbers for the telephone replay are:
855-859-2056 (domestic) and 404-537-3406 (international); the
passcode is 9168158. A webcast replay will also be archived on
www.exelixis.com for one year.
About Exelixis
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in
model system genetics, we established a broad drug discovery and
development platform that has served as the foundation for our
continued efforts to bring new cancer therapies to patients in
need. Our discovery efforts have resulted in four commercially
available products, CABOMETYX® (cabozantinib), COMETRIQ®
(cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO®
(esaxerenone), and we have entered into partnerships with leading
pharmaceutical companies to bring these important medicines to
patients worldwide. Supported by revenues from our marketed
products and collaborations, we are committed to prudently
reinvesting in our business to maximize the potential of our
pipeline. We are supplementing our existing therapeutic assets with
targeted business development activities and internal drug
discovery - all to deliver the next generation of Exelixis
medicines and help patients recover stronger and live longer.
Exelixis is a member of Standard & Poor’s (S&P) MidCap 400
index, which measures the performance of profitable mid-sized
companies. For more information about Exelixis, please visit
www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis,
Inc. on Facebook.
Exelixis, the Exelixis logo, CABOMETYX,
COMETRIQ and COTELLIC are registered U.S. trademarks. MINNEBRO is a
registered Japanese trademark.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200212005832/en/
Investors Contact: Susan Hubbard Executive Vice
President, Public Affairs & Investor Relations Exelixis, Inc.
650-837-8194 shubbard@exelixis.com
Media Contact: Hal Mackins For Exelixis, Inc.
415-994-0040 hal@torchcommunications.com
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Apr 2023 to Apr 2024